AL
Alma Yesodot Ltd.
KVSR | TA
Overview
Corporate Details
- ISIN(s):
- IL0011731457
- LEI:
- Country:
- Israel
- Address:
- HaBarzel 3, 6971005 Tel Aviv - Jaffa
- Website:
- https://www.almayesodot.co.il/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kvasir focuses on developing innovative medical devices and diagnostic technologies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-24 17:08 |
Regulatory News Service
Opening of Trading on April 27 2025-ALMA YESODOT B1
|
Hebrew (modern) | 118.8 KB | ||
| 2025-04-23 11:59 |
Regulatory News Service
Identifying Details of New Security-ALMA YESODOT B1
|
Hebrew (modern) | 87.5 KB | ||
| 2024-11-05 15:46 |
Regulatory News Service
Changes in the company's name and security, effective as of November 7, 2024
|
Hebrew (modern) | 108.5 KB | ||
| 2024-10-29 18:37 |
Regulatory News Service
The sector classification of the company will be changed, as of October 31, 202…
|
Hebrew (modern) | 121.3 KB | ||
| 2024-10-29 17:20 |
Regulatory News Service
Base price of 1 agora and unlimited price fluctuation
|
Hebrew (modern) | 90.8 KB | ||
| 2023-05-22 23:20 |
Report Publication Announcement
Frost and Sullivan is terminating coverage , following the completion of its co…
|
Hebrew (modern) | 174.5 KB | ||
| 2023-05-22 23:20 |
Pre-Annual General Meeting Information
Frost and Sullivan is terminating coverage , following the completion of its co…
|
Russian | 46.0 KB | ||
| 2023-03-23 21:00 |
Investor Presentation
Analysis update following financial report- price target is updated to NIS 22.7
|
English | 1.2 MB | ||
| 2023-03-23 21:00 |
Legal Proceedings Report
Analysis update following financial report- price target is updated to NIS 22.7
|
Russian | 71.0 KB | ||
| 2022-12-11 20:40 |
Investor Presentation
Analysis update following financial report- price target is updated to NIS 32.9…
|
English | 1.2 MB | ||
| 2022-12-11 20:40 |
Business and Financial Review
Analysis update following financial report- price target is updated to NIS 32.9…
|
Russian | 67.3 KB | ||
| 2022-08-30 20:47 |
Investor Presentation
Analysis update report ,target price is at 47.6NIS
|
English | 1.2 MB | ||
| 2022-08-30 20:47 |
Business and Financial Review
Analysis update report ,target price is at 47.6NIS
|
Russian | 63.9 KB | ||
| 2022-08-18 16:58 |
Investor Presentation
Presentation
|
English | 3.0 MB | ||
| 2022-08-18 16:58 |
Pre-Annual General Meeting Information
Presentation
|
Russian | 42.7 KB |
Automate Your Workflow. Get a real-time feed of all Alma Yesodot Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Alma Yesodot Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alma Yesodot Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom
NFX
United Kingdom
NFX
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America
NRIX
United States of America
NRIX
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary
NUTEX
Hungary
NUTEX
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America
NTRB
United States of America
NTRB
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America
NUVL
United States of America
NUVL
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America
NUVB
United States of America
NUVB
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565
Japan
4565
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
Switzerland
OBSN
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL
United States of America
OCUL
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden
ODI
Sweden
ODI